This announcement is a separate document:
歐康維視生物-B:自願性公告 OT-502於中國的III期臨床試驗達到主要終點
OCUMENSION-B: VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.